A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer

The investigational therapy uses a cold-temperature probe to kill a portion of prostate cancer cells and release tumor-specific neoantigens to facilitate an immune response.

SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10 in San Diego.

Login Or Register To Read Full Story